Group items tagged

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

Scotland has become the world's first country to introduce a simple blood test for Type 1 diabetes patients, enabling them to stop taking insulin by improving the accuracy of diagnosis. The routine C-peptide test, introduced today (November 1), will allow doctors to know how much insulin someone with diabetes is making themselves. The roll-out of test follows a two-year pilot study in NHS Lothian led by diabetes and endocrinology consultant Professor Mark Strachan. Strachan said: "C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment. In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy; this can be life-transforming."

The number of people in England identified as at risk for type 2 diabetes mellitus (T2DM) has increased by over half a million within a year, according to NHS figures. Data released by the National Diabetes Audit on June 12 showed that 3.6 million people registered with a GP were found to have non-diabetic hyperglycaemia (also known as pre-diabetes) in 2023, compared with 3.1 million people in 2022 - a notable 18 per cent increase or nearly 550,000 people. Among those under 40 years old, the figures showed an increase of almost 25 per cent from 173,166 in 2022 to 216,440 in 2023. People with non-diabetic hyperglycaemia have higher-than-normal blood sugar levels, and they are at greater risk for developing type 2 diabetes and cardiovascular diseases. Typically, this condition is detected through routine blood tests at GP surgeries.